Cytoskeleton Genes Underlying Onset and Progression in Multiple Neurodegenerative Disorders Discovered through Aitia’s Digital Twins to be Presented at SfN 2023
Somerville, MA, November 8, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its neurodegenerative disorders Digital Twins, including Alzheimer’s Disease (AD) and Parkinson Disease (PD), will be presented at the upcoming Society of Neuroscience (SfN) Conference, being held from […]
Prediction of Amyloid PET Positivity from Blood-Based Biomarkers, Proteomics, and Clinical Data Discovered through Aitia’s Digital Twins to be Presented at CTAD 2023
Somerville, MA, October 19, 2023: Aitia, the leader in the application of Causal AI and Digital Twins to discover and develop new drugs, announced today that data from its Alzheimer’s Disease Digital Twins will be presented at the upcoming Clinical Trials on Alzheimer’s Disease (CTAD), being held from October 24-27, 2023 in Boston. Aitia’s Digital […]
Webinar | From the beta-amyloid hypothesis to AI-driven discoveries of novel biomarkers and breakthrough drugs in Alzheimer’s Disease
Alzheimer’s disease research has taken center stage in the world of drug discovery and clinical development. The convergence of causal AI, supercomputing power, and multi-omic human data is allowing us to begin to unravel the molecular circuity of this debilitating disease in order to discover the next generation of breakthrough drugs and predictive biomarkers. In […]
Exploring the Frontiers of AI-driven Drug Discovery: A Conversation with Aitia on The Long Run Podcast
Colin Hill joined Luke Timmerman on “The Long Run” podcast, to explore Aitia’s journey and its impact on the realm of drug discovery. In this episode, Colin and Luke delve into the genesis of Aitia. From its humble beginnings to its current status as a pioneering in the industry. 🎧 If you would like to […]
Servier and Aitia Mobilize AI and Digital Twins to Treat Pancreatic Cancer
The French pharmaceutical group Servier and Aitia announced on May 17th a multi-year partnership agreement for the discovery and simulation of drugs in pancreatic cancer. It is based on the combination of Servier’s expertise in preclinical trials with Aitia’s technology, which is based on artificial intelligence and Gemini Digital Twins. Read more on the latest […]
Colin Hill Weighs in on the Future of Drug Discovery on the Patients Rising Podcast
Our CEO, Colin Hill was a special guest on the Patients Rising Podcast. In this week’s episode, Colin passionately shared his beliefs and vision for the future of medical research, highlighting the transformative potential of AI-powered clinical trials and the revolutionary power of Digital Twins. Tune in to the podcast episode now and discover how Digital […]
Open to Debate: Is the FDA’s Caution Hazardous to your Health?
During the COVID-19 pandemic, the Atlantic lambasted the US Food and Drug Administration for moving too slowly to approve vaccines with the provocative headline “The Death Toll of Delay.” Not long before, National Public Radio had run a piece titled “One-Third of New Drugs Had Safety Problems After FDA Approval.” As the agency tries to […]
World Congress: AI and Digital Twins to Drive the Next Generation Drug Discovery and Development
Watch Colin Hill’s talk at Charles River’s sixth Annual World Congress on May 11, 2023, in Cambridge, MA. Colin’s session focused on “Al and Digital Twins to Drive the Next Generation of Drug Discovery and Development”. The presentation was followed by a fireside chat with Julie Frearson, Chief Scientific Officer at Charles River Laboratories. This […]
Servier Doubles Up on Digital Twin Alliance with Aitia
The new project will focus on pancreatic cancer, and builds on a collaboration in the blood cancer multiple myeloma that was started by the two companies last year. Read more on the latest collaboration between Servier and Aitia, in Pharmaphorum article. Full article here. Picture Credit: Pharmaphorum
Companies to Focus on Therapeutic Targets Showing Cause and Effect
Aitia has been featured in Huntington’s Disease News for its collaboration with UCB to develop a new treatment for Huntington’s disease. The article highlights Aitia’s expertise in Causal AI as “a new branch of artificial intelligence that goes beyond establishing links between variables: It makes decisions and predictions based on cause and effect.” The collaboration […]